Supplementation of 1,25 dihydroxy vitamin D3 in patients with treatment naive early rheumatoid arthritis: A randomised controlled trial
International Journal of Rheumatic Diseases, 10/18/2011
GOPINATH K et al.
– Supplementation of 500 IU of 1,25 dihydroxy vitamin D3 daily to previously DMARD-naïve patients with early RA along with triple DMARD therapy results in a significantly higher pain relief at the end of 3 months. The number needed to treat for this additional pain relief was 5. The prevalence of vitamin D deficiency in the study population was 68.1%.
An open-labeled randomized trial comparing triple disease-modifying anti-rheumatic drug (DMARD) therapy and 500 IU 1,25 dihydroxy vitamin D3 + calcium combination versus triple DMARD and calcium alone
The primary outcome was time to pain relief by patients’ visual analogue scale (VAS)
Changes in VAS after first achievement of pain relief and after 3 months were noted
25 hydroxy-vitamin D levels were correlated with disease activity scor (DAS-28), adjusting for sun exposure
Comparisons between groups were done by Mann–Whitney test and independent samples test
Patients on vitamin D group (n = 59) had higher pain relief than the control group (n = 62) (50%vs. 30%, P = 0.006)
No significant difference in the time taken for initial pain relief between 2 groups
Occurrence of hypovitaminosis D in RA patients (68.1%) is comparable to published normal Indian prevalence
No correlation between 25 hydroxy vitamin D levels and disease activity
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.